Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propionibacterium Extract Gel vs GTN for Chronic Anal Fissure
NCT05616455Phase 4Completed
- Sponsor
- Treviso Regional Hospital
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Whole Cell Cancer Vaccines, Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised trial of propionibacterium extract in anal fissure (2 arms), sponsored by Treviso Regional Hospital. Primary endpoint: REALISE score at 40 days. Started Oct 2021; status: completed.
02
Drugs
propionibacterium extract
03
Conditions
anal fissure
Beyond the preview
Go deeper on NCT05616455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616455.